MDMA and the FDA: Resilient Refiles NDA for PTSD

In a major development for clinical psychedelic medicine, Resilient Pharmaceuticals has resubmitted its New Drug Application (NDA) to the Food and Drug Administration (FDA) for MDMA-assisted PTSD therapy. As reported by DoubleBlind Mag, this submission marks a second attempt to secure federal approval following an initial rejection in the summer of 2024. The company, previously known as Lykos Therapeutics and MAPS PBC, seeks approval for MDMA combined with talk therapy.

This refiling comes at a pivotal moment for mental health policy across the United States. While the FDA previously asked for a new Phase 3 trial, Resilient has taken a different approach to address agency concerns. For readers in Washington DC, Maryland, and Virginia, this national regulatory movement carries significant local legal and clinical implications.

The Regulatory Journey: From Rejection to Refiling

When the FDA denied the original application in 2024, it issued a Complete Response Letter outlining specific agency roadblocks. The FDA highlighted three main concerns: a failure to track "positive" side effects, insufficient proof of long-term effectiveness, and a study pool containing too many previous MDMA users and screening failures. These technical hurdles effectively stalled the commercial launch of the treatment.

Adding to the controversy, the academic journal Psychopharmacology retracted three Phase 2 papers in August 2024 due to protocol breaches. The retractions stemmed from researchers failing to report "adverse positive effects" and omitting protocol violations from published findings. Despite these setbacks, the company restructured its corporate entity and refined its submission strategy.

The New Data Strategy: External Studies and Phase 1 Trials

Rather than funding and conducting a costly new Phase 3 clinical trial, Resilient chose to leverage existing external datasets to satisfy FDA demands. The resubmission relies on long-term patient data from a Veterans Affairs study, alongside independent research datasets. To address safety tracking concerns, Resilient also completed a fresh Phase 1 clinical trial featuring 32 participants dedicated to monitoring unintended side effects.

Advocates and clinical experts have welcomed the renewed evaluation process. Betty Aldworth, co-executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), noted in an August press release that updated agency guidance reflects decades of scientific collaboration. She emphasized that federal drug regulation systems were not originally designed to evaluate pharmaceutical compounds delivered alongside psychotherapy.

Ismail Ali, J.D., co-executive director for MAPS, highlighted that broader clinical questions remain central to the field. He explained that MAPS focuses on therapist training standards, patient safety outcomes, and expanding access for individuals impacted by severe trauma. In a statement to Psychedelic Alpha, MAPS founder Rick Doblin maintained that original trial data remained valid despite historical blinding and reporting complexities.

Medical professionals have also expressed cautious optimism regarding the refiled NDA. Dr. Franklin King, Director of Training and Education at the Massachusetts General Hospital Center for the Neuroscience of Psychedelics, stated that available evidence supported approval in 2024. He emphasized that FDA approval would eliminate major research barriers that currently complicate rigorous MDMA studies.

Veterans advocates view the submission as a necessary lifeline for former service members facing severe trauma. Logan Davidson, policy director for Veterans Exploring Treatment Solutions (VETS), noted that conventional PTSD treatments often fail long-term patients. He stated that while the regulatory process must remain rigorous, veterans deserve access to science-backed therapeutic options.

Political Momentum and Federal Executive Orders

The regulatory review takes place within an unusually favorable political climate for psychedelic medicine. In July, the FDA finalized non-binding guidelines governing clinical trials for psychedelic compounds. Furthermore, President Donald Trump signed Executive Order 14401 in April, titled "Accelerating Medical Treatments for Serious Mental Illness," which explicitly instructs federal agencies to expedite psychedelic research and public access.

The executive order directs the FDA, the Department of Health and Human Services, the Drug Enforcement Administration, and the Department of Veterans Affairs to fast-track approvals. It specifically highlights "Right to Try" provisions for ibogaine and the deployment of Commissioner's National Priority Vouchers. Trump publicly acknowledged that a text message from podcaster Joe Rogan helped prompt the executive action.

Political and financial backing has also coalesced around Resilient Pharmaceuticals. Major shareholder Antonio Gracias, a former special government employee under Trump's Department of Government Efficiency (DOGE), orchestrated a financial takeover in May 2025 alongside British billionaire Christopher Hohn. If approved, Resilient plans to market its patented MDMA formulation under the commercial brand name "Rysanso."

What This Means for DC, Maryland and Virginia Residents

For residents across the National Capital Region, federal approval of MDMA-assisted therapy would fundamentally shift clinical access. Washington DC operates under unique municipal cannabis frameworks like Initiative 71, but clinical psychedelic therapies remain strictly under federal Schedule I oversight. FDA approval and subsequent DEA rescheduling would allow licensed medical centers in DC to administer Rysanso legally under clinical supervision.

In Maryland, where adult-use cannabis and medical programs are fully operational, state health regulators closely monitor federal drug approvals. The state hosts prominent medical centers and military health institutions that could quickly adopt approved MDMA protocols. Maryland veterans suffering from treatment-resistant PTSD would gain structured clinical access through certified therapeutic facilities.

Virginia hosts one of the largest veteran populations in the nation, making MDMA therapy access a critical policy topic. While Virginia legal frameworks do not permit non-regulated psychedelic sales, state lawmakers have increasingly shown interest in veteran-focused medical treatments. Federal FDA clearance would enable VA hospitals throughout Virginia to participate in official therapeutic rollouts.

How This Compares to Other States

State-level psychedelic policies vary dramatically across the country, creating a patchwork of legal frameworks. States like Oregon and Colorado have established state-regulated psilocybin programs independent of federal drug approval. However, these state-level frameworks operate outside the formal FDA pharmaceutical pipeline, creating distinct legal and insurance challenges for participants.

In contrast, Resilient’s pursuit of FDA approval targets complete federal legality and prescription integration. If approved, Rysanso would become available nationwide through standard medical prescriptions and certified therapy clinics. This prescription model contrasts sharply with decriminalization measures, offering formal insurance coverage pathways and nationwide standardized safety protocols.

Timeline and Next Steps

The resubmission of the New Drug Application officially resets the FDA’s formal review clock. The agency will evaluate the supplemental VA datasets, independent research, and Phase 1 safety data over the coming months. A final decision will determine whether MDMA becomes the first FDA-approved psychedelic-assisted treatment in modern American medicine.

If the FDA grants approval, the Drug Enforcement Administration must complete a mandatory rescheduling process within 90 days. Following DEA action, state health departments—including those in DC, Maryland, and Virginia—will issue clinical guidelines. Production, therapist certification, and facility credentialing would likely take several additional months before widespread patient availability.

Is MDMA currently legal for clinical use in DC, Maryland, or Virginia?

No, MDMA remains a Schedule I controlled substance under federal and state law. It cannot be legally prescribed or delivered outside of FDA-approved clinical trials. If the FDA approves Resilient's application, federal rescheduling will be required before clinical administration can begin in the DMV region.

What is Resilient Pharmaceuticals?

Resilient Pharmaceuticals is the clinical-stage pharmaceutical company leading the FDA application for MDMA-assisted therapy. The organization was formerly known as Lykos Therapeutics and originally operated as MAPS Public Benefit Corporation (MAPS PBC).

Why did the FDA reject the initial application in 2024?

The FDA issued a Complete Response Letter in summer 2024 citing concerns over side-effect tracking, long-term efficacy data, and participant selection bias. The agency requested additional data and clearer safety documentation, which Resilient addressed in its latest submission.

What is Rysanso?

Rysanso is the commercial brand name trademarked by Resilient Pharmaceuticals for its patented MDMA formulation. If the FDA approves the treatment, the medication will be marketed and distributed under this official name.

How does Executive Order 14401 affect psychedelic therapy?

Executive Order 14401 directs federal health and regulatory agencies to expedite research, clinical evaluation, and public access to treatments for serious mental illness. The order specifically urges faster review cycles for promising psychedelic compounds like MDMA and ibogaine.

Final Takeaway

The resubmission of MDMA-assisted therapy to the FDA represents a critical crossroads for mental health treatment in the United States. While regulatory hurdles remain, changing federal executive priorities and robust veteran advocacy have reshaped the review landscape. Residents and medical providers in DC, Maryland, and Virginia should monitor upcoming FDA announcements as federal decisions directly shape local clinical availability.

Source: DoubleBlind Mag

---

Written by DC Metro Cannabis AI

Bud Lords AI Cannabis News Writer

Expert on DC, Maryland, and Virginia cannabis laws, dispensaries, and local market. Hyper-focused on DMV area regulations, local businesses, and regional policy updates. Always includes specific implications for each jurisdiction.

Expertise: dc · maryland · virginia · dmv · local · regional

View more from DC Metro Cannabis AI

This AI-assisted article was created using the named Bud Lords newsroom personality and reviewed under Bud Lords editorial standards.